DOCSLIB.ORG

How Do Ssris Cause Sexual Dysfunction?

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
How Do Ssris Cause Sexual Dysfunction? How do SSRIs cause sexual dysfunction? Understanding key mechanisms can help improve patient adherence, prognosis lthough selective serotonin reuptake inhibitors (SSRIs) are frequently prescribed1 and are better Atolerated than older antidepressants, side effects such as sexual dysfunction limit patient acceptance of these medications. DSM-IV-TR categorizes medication-induced sexual dysfunction as a type of substance-induced sexual dysfunction.2 These dysfunctions are characterized by im- pairment of various sexual response phases (Table 1).2,3 Estimating the true incidence and prevalence of SSRI-related sexual dysfunction can be difficult. Zimmerman et al4 compared psychiatrists’ clinical assess- ments of depressed patients receiving ongoing treatment with results of a standardized side effects questionnaire and found that even though psychiatrists regularly in- quired about sexual side effects, on the questionnaire © 2010 PHOTOS.COM patients reported higher rates of almost all sexual dys- Deepak Prabhakar, MD, MPH functions. The incidence of SSRI-induced sexual dysfunc- Chief Resident, Outpatient Department tion also can be difficult to ascertain because some sexual Richard Balon, MD dysfunctions frequently accompany a primary psychiat- Professor ric disorder5 or physical illness. Balon6 suggested that the • • • • incidence of SSRI-associated sexual dysfunction is 30% to Department of Psychiatry and Behavioral 50%, although others have reported higher incidences. Neurosciences Few quality studies have focused on identifying the ex- Wayne State University act nature and causes of SSRI treatment-emergent sexual Detroit, MI dysfunction. This article describes mechanisms that may be fundamental to SSRI-associated sexual dysfunction. Not just serotonin Although SSRIs are relatively selective for the serotoner- Current Psychiatry 30 December 2010 gic system, they affect other neurotransmitter systems Table 1 Sexual dysfunction and the sexual response cycle Phase Description Dysfunction/disorder Desire Characterized by sexual Hypoactive sexual desire disorder fantasies and the desire Sexual aversion disorder to have sex Hypoactive sexual desire disorder due to a general medical condition Substance-induced sexual dysfunction with impaired desire Excitement Subjective sense Female sexual arousal disorder of sexual pleasure Erectile disorder and accompanying physiologic changes Erectile disorder due to a general medical condition Dyspareunia due to a general medical condition Substance-induced sexual dysfunction with impaired arousal Clinical Point Orgasm Peaking of sexual Female orgasmic disorder pleasure with release Although SSRIs are Male orgasmic disorder of sexual tension relatively selective Premature ejaculation Other sexual dysfunction due to a general medical for serotonin, they condition also affect other Substance-induced sexual dysfunction with impaired neurotransmitter orgasm systems Resolution A sense of general Postcoital dysphoria relaxation, well-being, Postcoital headache and muscle relaxation Source: References 2,3 as well (Table 2, page 32).7 For example, at imal studies of the impact of serotonin ago- high dosages paroxetine is believed to block nist and antagonist agents on mounting and norepinephrine reuptake, and it has a clini- ejaculation have reported inconsistent re- cally significant anticholinergic effect. Also, sults.10 Differential roles of 5-HT1 and 5-HT2 sertraline is a potent reuptake inhibitor of receptor activation on sexual behavior may dopamine.8 Therefore, our discussion will explain some of these inconsistencies.8 How- include these neurotransmitters. ever, 1 study found that antiserotonergic In their dual control model of male sex- pharmacologic agents enhance sexual exci- ual response, Bancroft et al9 discuss the in- tation in laboratory animals,11 and a separate terplay between excitatory and inhibitory study showed that severing serotonergic mechanisms at the central and peripheral axons in the medial forebrain bundle in male levels. For example, they describe the role rats facilitated ejaculation.12 of norepinephrine mediation in the cen- Monteiro et al13 found a high incidence of tral arousal system via the disinhibition of anorgasmia in previously orgasmic patients dopaminergic and a possible testosterone after they received clomipramine, which mechanism. They also point to possible in- may be partially attributed to the drug’s se- hibition of central sexual arousal by neuro- rotonergic action. This prompted research- peptidergic and serotonergic mechanisms. ers to hypothesize that central serotonergic Evidence linking serotonin to sexual dys- tone inhibits sexual behavior. However, function is inconclusive because there are no based on current evidence, it would be best exclusively serotonergic agents. Drugs fre- to consider serotonin as having a modulat- quently used to test these hypotheses often ing effect10—as opposed to a complete in- affect other neurotransmitters, which means hibitory effect—on human sexual behavior. Current Psychiatry conclusions are not specific to serotonin. An- Regarding the parasympathetic system, Vol. 9, No. 12 31 Table 2 structurally similar to cytochrome P450 (CYP450). Paroxetine is a strong CYP2D6 in- Neurotransmitters affected hibitor, which contributes to low nitric oxide by SSRIs levels in patients taking the drug.16 SSRI Neurotransmitters Citalopram 5-HT Escitalopram 5-HT SSRIs and sexual response SSRIs and Fluoxetine 5-HT, NE, DA Because decreased libido is part of depres- sexual dysfunction Fluvoxamine 5-HT sive psychopathology,5 it is difficult to attri- Paroxetine 5-HT, NE, Ach bute loss of sexual desire directly to SSRIs. Sertraline 5-HT, NE, DA Nonetheless, SSRIs are associated with a 5-HT: serotonin; Ach: acetylcholine; DA: dopamine; risk of clinically significant loss of sexual NE: norepinephrine; SSRIs: selective serotonin reuptake inhibitors desire that may resemble moderate to se- Source: Reference 7 vere hypoactive sexual desire disorder.17 Reduced mesolimbic dopaminergic activity as a result of inhibitory serotonergic mid- Clinical Point it was long believed that cholinergic inner- brain raphe nuclei projections is 1 possible SSRIs may reduce vations mediate penile erection. However, cause.18 This hypothesis has lead investi- levels of nitric oxide, a more plausible hypothesis may be that gators to examine drug targets in the CNS parasympathetic cholinergic transmission for hypoactive sexual desire disorder that which is necessary at best has a modulating effect when other would inhibit serotonergic tone and lead to for mediating penile neurotransmitters—primarily the adrener- brain dopaminergic system stimulation. vasculature changes gic system—are affected by concomitant Another putative hypothesis for SSRI- 10 needed for erection pharmacologic interventions. Segraves induced loss of sexual desire is the role of proposed that cholinergic potentiating of 5-HT1A receptor-mediated norepinephrine adrenergic activity may be primarily re- neurotransmission. Because the sympathetic sponsible for bethanechol-induced rever- nervous system is believed to be involved sal of SSRI-induced sexual dysfunction. in genital arousal in women, a small study The adrenergic system is believed to play analyzed the effect of sympathetic activa- a role in penile erection and ejaculation.10 tion on SSRI-induced sexual dysfunction.19 Adrenergic fibers innervate the vas deferens, Women who received paroxetine and sertra- seminal vesicles, trigone of the urinary blad- line—both are highly selective for 5-HT1A— der, and proximal urethra.14 Penile contrac- showed improvement in sexual arousal and tile and erectile tissue is richly innervated by orgasm after taking ephedrine before sex- the adrenergic nerve fibers.10 Ejaculation is ual activity.19 Women who took fluoxetine, 10 mediated by α1-adrenergic receptors. which is less selective for 5-HT1A, show no change or decreased sexual function. SSRIs are associated with reduced noc- The role of nitric oxide synthase turnal penile erections and severe erectile The advent of sildenafil underscored the im- dysfunction, but the relationship is not ro- portance of nitric oxide-mediated relaxation bust.17 SSRI-induced suppression of rapid pathways in treating erectile dysfunction. eye movement sleep20 may partially explain Nitric oxide plays an important role in me- reduced nocturnal and early morning erec- ONLINE ONLY diating the penile vasculature changes es- tions. Supraspinal areas and preganglionic sential for erection and also is hypothesized sacral neurons involved in sexual excite- Discuss this article at to promote penile smooth muscle relaxation ment also are reported to have substantial http://CurrentPsychiatry. blogspot.com via cyclic guanosine monophosphate, there- serotonergic activity, which suggests that by contributing to physiologic erection.15 serotonin has a direct role in erectile dys- Paroxetine is known to inhibit nitric oxide function at a comparative peripheral level.21 synthase, which reduces nitric oxide levels. However, a recent study17 found no differ- The exact mechanism of this interaction re- ence in flaccid and peak systolic velocity mains unclear; however, it is hypothesized when comparing patients taking SSRIs with Current Psychiatry 32 December 2010 that 3 nitric oxide synthase isoenzymes are those who do not. This indicates that SSRIs’ affect on spontaneous and sexually aroused Table 3 erections may be mediated at both central and peripheral levels. Other than SSRIs, which medications
Load more

Recommended publications
  • Physiology of Female Sexual Function and Dysfunction
    International Journal of Impotence Research (2005) 17, S44–S51 & 2005 Nature Publishing Group All rights reserved 0955-9930/05 $30.00 www.nature.com/ijir Physiology of female sexual function and dysfunction JR Berman1* 1Director Female Urology and Female Sexual Medicine, Rodeo Drive Women’s Health Center, Beverly Hills, California, USA Female sexual dysfunction is age-related, progressive, and highly prevalent, affecting 30–50% of American women. While there are emotional and relational elements to female sexual function and response, female sexual dysfunction can occur secondary to medical problems and have an organic basis. This paper addresses anatomy and physiology of normal female sexual function as well as the pathophysiology of female sexual dysfunction. Although the female sexual response is inherently difficult to evaluate in the clinical setting, a variety of instruments have been developed for assessing subjective measures of sexual arousal and function. Objective measurements used in conjunction with the subjective assessment help diagnose potential physiologic/organic abnormal- ities. Therapeutic options for the treatment of female sexual dysfunction, including hormonal, and pharmacological, are also addressed. International Journal of Impotence Research (2005) 17, S44–S51. doi:10.1038/sj.ijir.3901428 Keywords: female sexual dysfunction; anatomy; physiology; pathophysiology; evaluation; treatment Incidence of female sexual dysfunction updated the definitions and classifications based upon current research and clinical practice.
    [Show full text]
  • Sexual Disorders and Gender Identity Disorder
    CHAPTER :13 Sexual Disorders and Gender Identity Disorder TOPIC OVERVIEW Sexual Dysfunctions Disorders of Desire Disorders of Excitement Disorders of Orgasm Disorders of Sexual Pain Treatments for Sexual Dysfunctions What are the General Features of Sex Therapy? What Techniques Are Applied to Particular Dysfunctions? What Are the Current Trends in Sex Therapy? Paraphilias Fetishism Transvestic Fetishism Exhibitionism Voyeurism Frotteurism Pedophilia Sexual Masochism Sexual Sadism A Word of Caution Gender Identity Disorder Putting It Together: A Private Topic Draws Public Attention 177 178 CHAPTER 13 LECTURE OUTLINE I. SEXUAL DISORDERS AND GENDER-IDENTITY DISORDER A. Sexual behavior is a major focus of both our private thoughts and public discussions B. Experts recognize two general categories of sexual disorders: 1. Sexual dysfunctions—problems with sexual responses 2. Paraphilias—repeated and intense sexual urges and fantasies to socially inappropri- ate objects or situations C. In addition to the sexual disorders, DSM includes a diagnosis called gender identity dis- order, a sex-related pattern in which people feel that they have been assigned to the wrong sex D. Relatively little is known about racial and other cultural differences in sexuality 1. Sex therapists and sex researchers have only recently begun to attend systematically to the importance of culture and race II. SEXUAL DYSFUNCTIONS A. Sexual dysfunctions are disorders in which people cannot respond normally in key areas of sexual functioning 1. As many as 31 percent of men and 43 percent of women in the United States suffer from such a dysfunction during their lives 2. Sexual dysfunctions typically are very distressing and often lead to sexual frustra- tion, guilt, loss of self-esteem, and interpersonal problems 3.
    [Show full text]
  • Effects of Expressive Writing on Sexual Dysfunction, Depression, and PTSD in Women with a History of Childhood Sexual Abuse: Results from a Randomized Clinical Trial
    2177 ORIGINAL RESEARCH—PSYCHOLOGY Effects of Expressive Writing on Sexual Dysfunction, Depression, and PTSD in Women with a History of Childhood Sexual Abuse: Results from a Randomized Clinical Trial Cindy M. Meston, PhD, Tierney A. Lorenz, MA, and Kyle R. Stephenson, MA Department of Psychology, University of Texas at Austin, Austin, TX, USA DOI: 10.1111/jsm.12247 ABSTRACT Introduction. Women with a history of childhood sexual abuse (CSA) have high rates of depression, posttraumatic stress disorder, and sexual problems in adulthood. Aim. We tested an expressive writing-based intervention for its effects on psychopathology, sexual function, satisfaction, and distress in women who have a history of CSA. Methods. Seventy women with CSA histories completed five 30-minute sessions of expressive writing, either with a trauma focus or a sexual schema focus. Main Outcome Measures. Validated self-report measures of psychopathology and sexual function were conducted at posttreatment: 2 weeks, 1 month, and 6 months. Results. Women in both writing interventions exhibited improved symptoms of depression and posttraumatic stress disorder (PTSD). Women who were instructed to write about the impact of the abuse on their sexual schema were significantly more likely to recover from sexual dysfunction. Conclusions. Expressive writing may improve depressive and PTSD symptoms in women with CSA histories. Sexual schema-focused expressive writing in particular appears to improve sexual problems, especially for depressed women with CSA histories. Both treatments are accessible, cost-effective, and acceptable to patients. Meston CM, Lorenz TA, and Stephenson KR. Effects of expressive writing on sexual dysfunction, depression, and PTSD in women with a history of childhood sexual abuse: Results from a randomized clinical trial.
    [Show full text]
  • GC-MS Analysis of an Herbal Medicinal
    SUPPLEMENT TO October 2014 LCGC North America | LCGC Europe | Spectroscopy GC–MS Analysis of an Herbal Medicine Screening Clandestine Drug Operations with Portable Ambient Sampling MS Targeted Protein Quantifi cation Using MS with Data- Independent Acquisition Determination of Methylxanthines and Cotinine in Human Plasma by SPE and LC–MS-MS magentablackcyanyellow ES501473_SpecCTMS1014_CV1.pgs 09.18.2014 21:10 ADV To Unravel the Proteome, Take an Integrated Approach Solving the complexity of the proteome is far more challenging than ESI-Qq-TOF fi rst imagined. That is why Bruker offers a portfolio of integrated MALDI TOF-TOF complementary technologies that together comprise a multidimensional ESI-ITMS toolbox optimized to unlock the proteome’s complexity. Bottom-up and top-down analyses, intact protein analysis as well as in-depth protein ESI-MALDI-FTMS characterization come together to illuminate a more detailed picture of Bioinformatics the proteome, complete with biological context and confi dence in the quality of your MS data. Contact us for solutions to your proteomics challenges. www.bruker.com Proteomics Innovation with Integrity magentablackcyanyellow ES502017_SPECCTMS1014_CV2_FP.pgs 09.19.2014 19:01 ADV magentablackcyanyellow ES502015_SPECCTMS1014_003_FP.pgs 09.19.2014 19:01 ADV 4 Current Trends in Mass Spectrometry October 2014 www.spectroscopyonline.com PUBLISHING & SALES ® 485F US Highway One South, Suite 210, Iselin, NJ 08830 (732) 596-0276, Fax: (732) 647-1235 Michael J. Tessalone Science Group Publisher, [email protected] Edward Fantuzzi Publisher, [email protected] Stephanie Shaffer East Coast Sales Manager, [email protected] (774) 249-1890 Lizzy Thomas MANUSCRIPTS: To discuss possible article topics or obtain manuscript preparation Account Executive, [email protected] guidelines, contact the editorial director at: (732) 346-3020, e-mail: [email protected].
    [Show full text]
  • Isoflurane Produces Antidepressant Effects and Induces Trkb Signaling in Rodents
    bioRxiv preprint doi: https://doi.org/10.1101/084525; this version posted July 11, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Isoflurane produces antidepressant effects and induces TrkB signaling in rodents Hanna Antilaa, Maria Ryazantsevaa,b, Dina Popovaa, Pia Sipiläa, Ramon Guiradoa, Samuel Kohtalaa,b, Ipek Yalcinc, Jesse Lindholma, Liisa Vesaa, Vinicius Satod, Joshua Cordeirae, Henri Autioa, Mikhail Kislina, Maribel Riose, Sâmia Jocad, Plinio Casarottoa, Leonard Khirouga, Sari Lauria,b, Tomi Tairaa,f, Eero Castréna* and Tomi Rantamäkia,b* aNeuroscience Center, P.O. Box 56, FI-00014 University of Helsinki, Helsinki, Finland. bDivision of Physiology and Neuroscience, Department of Biosciences, Faculty of Biological and Environmental Sciences, P.O. Box 66, FI-00014 University of Helsinki, Helsinki, Finland. cInstitut des Neurosciences Cellulaires et Intégratives, Centre National de la Recherche Scientifique, FR-67084 Strasbourg Cedex, France. dSchool of Pharmaceutical Sciences of Ribeirão Preto 14040-903, Brazil. eTufts University, Boston, MA, USA. fDepartment of Veterinary Biosciences, Faculty of Veterinary Medicine P.O. Box 66, FI-00014 University of Helsinki, Helsinki, Finland. *To whom correspondence should be addressed at: Eero Castrén ([email protected]) or Tomi Rantamäki ([email protected]) A brief burst-suppressing isoflurane anesthesia has been shown to rapidly alleviate symptoms of depression in a subset of patients, but the neurobiological basis of these observations remains obscure. We show that a single isoflurane anesthesia produces antidepressant-like behavioural effects in the learned helplessness paradigm and regulates molecular events implicated in the mechanism of action of rapid-acting antidepressant ketamine: activation of brain-derived neurotrophic factor (BDNF) receptor TrkB, facilitation of mammalian target of rapamycin (mTOR) signaling pathway and inhibition of glycogen synthase kinase 3β (GSK3β).
    [Show full text]
  • Medicine-Review-Dapoxetine.Pdf
    East & South East England Specialist Pharmacy Services East of England, London, South Central & South East Coast East Anglia Medicines Information Service Medicine Review Medicine / Trade name Dapoxetine / Priligy Manufacturer Menarini Document status Reviewed at Suffolk CCGs D&TC 22 January 2014 and CPG 14 April 2014 Date of last revision 15 January 2014 Traffic light decision Double red – Prescribing not supported in either general practice or secondary/tertiary care Prescribers rating Nothing new Mechanism of action Dapoxetine is a potent selective serotonin reuptake inhibitor (SSRI). Human ejaculation is primarily mediated by the sympathetic nervous system. The ejaculatory pathway originates from a spinal reflex centre, mediated by the brain stem, which is influenced initially by a number of nuclei in the brain (medial preoptic and paraventricular nuclei). The mechanism of action of dapoxetine in premature ejaculation is presumed to be linked to the inhibition of neuronal reuptake of serotonin and the subsequent potentiation of the neurotransmitter's action at pre− and postsynaptic receptors [1]. Licensed indication Dapoxetine is indicated for the treatment of premature ejaculation (PE) in adult men aged 18 to 64 years [1]. Dosage The recommended starting dose for all patients is 30 mg, taken as needed approximately 1 to 3 hours prior to sexual activity. Treatment with dapoxetine should not be initiated with the 60 mg dose [1]. Dapoxetine is not intended for continuous daily use. Dapoxetine should be taken only when sexual activity is anticipated dapoxetine must not be taken more frequently than once every 24 hours. If the individual response to 30 mg is insufficient and the patient has not experienced moderate or severe adverse reactions or prodromal symptoms suggestive of syncope, the dose may be increased to a maximum recommended dose of 60 mg taken as needed approximately 1 to 3 hours prior to sexual activity.
    [Show full text]
  • Diagnostic and Management Guidelines for Mental Disorders in Primary Care
    Diagnostic and Management Guidelines for Mental Disorders in Primary Care ICD-10 Chapter V ~rimary Care Version Published on behalf of the World Health Organization by Hogrefe & Huber Publishers World Health Organization Hogrefe & Huber Publishers Seattle . Toronto· Bern· Gottingen Library of Congress Cataloging-in-Publication Data is available via the Library of Congress Marc Database under the LC Catalog Card Number 96-77394 Canadian Cataloguing in Publication Data Main entry under title: Diagnostic and management guidelines for mental disorders in primary care: ICD-lO chapter V, primary care version ISBN 0-88937-148-2 1. Mental illness - Classification. 2. Mental illness - Diagnosis. 3. Mental illness - Treatment. I. World Health Organization. 11. Title: ICD-ten chapter V, primary care version. RC454.128 1996 616.89 C96-931353-5 The correct citation for this book should be as follows: Diagnostic and Management Guidelines for Mental Disorders in Primary Care: ICD-lO Chapter V Primary Care Version. WHO/Hogrefe & Huber Publishers, Gottingen, Germany, 1996. © Copyright 1996 by World Health Organization All rights reserved. Hogrefe & Huber Publishers USA: P.O. Box 2487, Kirkland, WA 98083-2487 Phone (206) 820-1500, Fax (206) 823-8324 CANADA: 12 Bruce Park Avenue, Toronto, Ontario M4P 2S3 Phone (416) 482-6339 SWITZERLAND: Langgass-Strasse 76, CH-3000 Bern 9 Phone (031) 300-4500, Fax (031) 300-4590 GERMANY: Rohnsweg 25,0-37085 Gottingen Phone (0551) 49609-0, Fax (0551) 49609-88 No part of this book may be translated, reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without the written permission from the copyright holder.
    [Show full text]
  • Alprazolam-Induced Dose-Dependent Anorgasmia: Case Analysis Kenneth R
    BJPsych Open (2018) 4, 274–277. doi: 10.1192/bjo.2018.35 Alprazolam-induced dose-dependent anorgasmia: case analysis Kenneth R. Kaufman, Melissa Coluccio, Michelle Linke, Elizabeth Noonan, Ronke Babalola and Rehan Aziz Background increasing alprazolam to 2.5 mg total daily dose, the patient Sexual dysfunctions are associated with multiple medical and reported anorgasmia. Anorgasmia was alprazolam dose- psychiatric disorders, as well as pharmacotherapies used to dependent, as anorgasmia resolved with reduced weekend treat these disorders. Although sexual dysfunctions negatively dosing (1 mg b.i.d. Saturday/1.5 mg total daily dose Sunday). affect both quality of life and treatment adherence, patients infrequently volunteer these symptoms and clinicians do not Conclusions pose directed questions to determine their presence or severity. Sexual dysfunction is an important adverse effect negatively This issue is especially important in psychiatric patients, for influencing therapeutic outcome. This case reports alprazolam- whom most common psychotropics may cause sexual dys- induced dose-dependent anorgasmia. Clinicians/patients should functions (antidepressants, antipsychotics, anxiolytics and be aware of this adverse effect. Routine sexual histories are mood-stabilising agents). There is limited literature addressing indicated. benzodiazepines, and alprazolam in particular. Declaration of interest Aims None. To report dose-dependent alprazolam anorgasmia. Method Keywords Case analysis with PubMed literature review. Alprazolam; benzodiazepine; sexual dysfunction; anorgasmia; adverse effect; nonadherence; anxiety disorder, major depres- Results sive disorder; obsessive–compulsive disorder, attention-deficit A 30-year-old male psychiatric patient presented with new-onset hyperactivity disorder; clinical care; education. anorgasmia in the context of asymptomatic generalised anxiety disorder, social anxiety, panic disorder with agoraphobia, Copyright and usage obsessive–compulsive disorder, major depression in remission, © The Royal College of Psychiatrists 2018.
    [Show full text]
  • Activation of 5-HT2C (But Not 5-HT1A) Receptors in the Amygdala Enhances Fear-Induced Antinociception: Blockade with Local 5-HT2C Antagonist Or Systemic fluoxetine
    Neuropharmacology 135 (2018) 376e385 Contents lists available at ScienceDirect Neuropharmacology journal homepage: www.elsevier.com/locate/neuropharm Activation of 5-HT2C (but not 5-HT1A) receptors in the amygdala enhances fear-induced antinociception: Blockade with local 5-HT2C antagonist or systemic fluoxetine Lígia Renata Rodrigues Tavares a, b, Daniela Baptista-de-Souza a, c, * Azair Canto-de-Souza a, b, c, d, a Psychobiology Group, Department of Psychology/CECH- Federal University of Sao~ Carlos-UFSCar, Sao~ Carlos, Sao~ Paulo, 13565-905, Brazil b Joint Graduate Program in Physiological Sciences UFSCar/UNESP, Sao~ Carlos, Sao~ Paulo, 13565-905, Brazil c Neuroscience and Behavioral Institute-IneC, Ribeirao~ Preto, Sao~ Paulo, 14040-901, Brazil d Program in Psychology UFSCar, Sao~ Carlos, Sao~ Paulo, 13565-905, Brazil article info abstract Article history: It is well-known that the exposure of rodents to threatening environments [e.g., the open arm of the Received 17 August 2017 elevated-plus maze (EPM)] elicits pain inhibition. Systemic and/or intracerebral [e.g., periaqueductal gray Received in revised form matter, amygdala) injections of antiaversive drugs [e.g., serotonin (5-HT) ligands, selective serotonin 5 March 2018 reuptake inhibitors (SSRIs)] have been used to change EPM-open arm confinement induced anti- Accepted 6 March 2018 nociception (OAA). Here, we investigated (i) the role of the 5-HT and 5-HT receptors located in the Available online 13 March 2018 1A 2C amygdaloid complex on OAA as well as (ii) the effects of systemic pretreatment with fluoxetine (an SSRI) on the effects of intra-amygdala injections of 8-OH-DPAT (a 5-HT1A agonist) or MK-212 (a 5-HT2C agonist) Keywords: fi Amygdala on nociception in mice con ned to the open arm or enclosed arm of the EPM.
    [Show full text]
  • Patient Group Direction for CLARITHROMYCIN (Version 03) Valid from 1 October 2019 – 30 September 2021
    Patient Group Direction for CLARITHROMYCIN (Version 03) Valid From 1 October 2019 – 30 September 2021 Version Control This PGD has been FCMS agreed by the following PDS Medical organisations Doncaster CCG East Lancashire CCG Change history 28/08/17 V02 Review. Adjusted dose and duration to match local guidance. Minor editing changes. 18/09/17 V02 Adjust inclusion criteria to match local guidance. 21/09/17 V02 Adjustments to treatment duration to match local guidance. 29/05/2019 V03 Revalidated 30/05/2019 Page 1 of 9 Patient Group Direction for CLARITHROMYCIN (Version 03) Valid From 1 October 2019 – 30 September 2021 CLINICAL CONTENT OF PATIENT GROUP DIRECTION Staff Characteristics Qualifications Registered nurse, Paramedic practitioner, ECP (Paramedic) or Nurse practitioner Specialist competencies Received training to undertake administration and supply of medicines or qualifications under PGD. Has undertaken appropriate training to carry out clinical assessment of patient, leading to diagnosis. Also that such diagnosis requires treatment according to the indications listed in this PGD. Continuing training and The practitioner should be aware of any change to the recommendations for education the medicine listed. It is the responsibility of the individual to keep up to date with continued professional development and to work within the limitations of individual scope or practice. Clinical Details Indication Treatment of skin, soft tissue or wound infections, acute bronchitis, community acquired pneumonia or exacerbations of COPD. Antibiotic alternative for patients hypersensitive to penicillins or cephalosporins or where these are unsuitable. Inclusion criteria Patients with skin, soft tissue or wound infections: Consider whether wound infections are clinically necessary to treat.
    [Show full text]
  • Paradoxical Actions of the Serotonin Precursor 5-Hydroxytryptophan on the Activity of Identified Serotonergic Neurons in a Simple Motor Circuit
    The Journal of Neuroscience, February 15, 2000, 20(4):1622–1634 Paradoxical Actions of the Serotonin Precursor 5-hydroxytryptophan on the Activity of Identified Serotonergic Neurons in a Simple Motor Circuit David J. Fickbohm and Paul S. Katz Department of Biology, Georgia State University, Atlanta, Georgia 30302 Neurotransmitter synthesis is regulated by a variety of factors, cated an increase in a putative 5-HT electrochemical signal yet the effect of altering transmitter content on the operation of during swim CPG activation. Paradoxically, the spiking activity neuronal circuits has been relatively unexplored. We used elec- of the serotonergic neurons decreased to a single burst at the trophysiological, electrochemical, and immunohistochemical onset of the rhythmic motor program, whereas the overall techniques to investigate the effects of augmenting the seroto- duration of the episode remained about the same. 5-HTP treat- nin (5-HT) content of identified serotonergic neurons embed- ment gradually reduced the rhythmicity of the CPG output. ded in a simple motor circuit. The dorsal swim interneurons Thus, more serotonin did not result in a more robust swim (DSIs) are serotonergic neurons intrinsic to the central pattern motor program, suggesting that serotonin synthesis must be generator (CPG) for swimming in the mollusc Tritonia diom- kept within certain limits for the circuit to function correctly and edea. As expected, treatment with the serotonin precursor indicating that altering neurotransmitter synthesis can have 5-hydroxytryptophan (5-HTP) increased the intensity of seroto- serious consequences for the output of neural networks. nin immunolabeling and enhanced the potency of synaptic and Key words: intrinsic neuromodulation; central pattern gener- modulatory actions elicited by the DSIs.
    [Show full text]
  • Rezolsta, INN-Darunavir Cobicistat
    ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT REZOLSTA 800 mg/150 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 800 mg of darunavir (as ethanolate) and 150 mg of cobicistat. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet (tablet). Pink oval shaped tablet of 23 mm x 11.5 mm, debossed with “800” on one side and “TG” on the other side. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications REZOLSTA is indicated, in combination with other antiretroviral medicinal products, for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults aged 18 years or older. Genotypic testing should guide the use of REZOLSTA (see sections 4.2, 4.4 and 5.1). 4.2 Posology and method of administration Therapy should be initiated by a healthcare provider experienced in the management of HIV infection. Posology ART-naïve patients The recommended dose regimen is one film-coated tablet of REZOLSTA once daily taken with food. ART-experienced patients One film-coated tablet of REZOLSTA once daily taken with food may be used in patients with prior exposure to antiretroviral medicinal products, but without darunavir resistance associated mutations (DRV-RAMs)* and who have plasma HIV-1 RNA < 100,000 copies/ml and CD4+ cell count ≥ 100 cells x 106/l (see section 4.1). * DRV-RAMs: V11I, V32I, L33F, I47V, I50V, I54M, I54L, T74P, L76V, I84V, L89V. In all other ART-experienced patients or if HIV-1 genotype testing is not available, the use of REZOLSTA is not appropriate and another antiretroviral regimen should be used.
    [Show full text]